BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23295344)

  • 21. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families.
    Kiuru M; Lehtonen R; Arola J; Salovaara R; Järvinen H; Aittomäki K; Sjöberg J; Visakorpi T; Knuutila S; Isola J; Delahunt B; Herva R; Launonen V; Karhu A; Aaltonen LA
    Cancer Res; 2002 Aug; 62(16):4554-7. PubMed ID: 12183404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer.
    Alam NA; Olpin S; Rowan A; Kelsell D; Leigh IM; Tomlinson IP; Weaver T
    J Mol Diagn; 2005 Oct; 7(4):437-43. PubMed ID: 16237213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fumarate hydratase immunohistochemical staining may help to identify patients with multiple cutaneous and uterine leiomyomatosis (MCUL) and hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome.
    Llamas-Velasco M; Requena L; Kutzner H; Schärer L; Rütten A; Hantschke M; Paredes BE; Mentzel T
    J Cutan Pathol; 2014 Nov; 41(11):859-65. PubMed ID: 25292446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidetector CT Characteristics of Fumarate Hydratase-Deficient Renal Cell Carcinoma and Papillary Type II Renal Cell Carcinoma.
    Yang L; Li XM; Hu YJ; Zhang MN; Yao J; Song B
    Korean J Radiol; 2021 Dec; 22(12):1996-2005. PubMed ID: 34668351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues.
    Liu X; Cao L; Ni J; Liu N; Zhao X; Wang Y; Zhu L; Wang L; Wang J; Yue Y; Cai Y; Jin J
    Int J Oncol; 2013 Dec; 43(6):1925-34. PubMed ID: 24101097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BIGH3 is overexpressed in clear cell renal cell carcinoma.
    Yamanaka M; Kimura F; Kagata Y; Kondoh N; Asano T; Yamamoto M; Hayakawa M
    Oncol Rep; 2008 Apr; 19(4):865-74. PubMed ID: 18357369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer.
    Ahvenainen T; Lehtonen HJ; Lehtonen R; Vahteristo P; Aittomäki K; Baynam G; Dommering C; Eng C; Gruber SB; Grönberg H; Harvima R; Herva R; Hietala M; Kujala M; Kääriäinen H; Sunde L; Vierimaa O; Pollard PJ; Tomlinson IP; Björck E; Aaltonen LA; Launonen V
    Cancer Genet Cytogenet; 2008 Jun; 183(2):83-8. PubMed ID: 18503824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients.
    Ylisaukko-oja SK; Kiuru M; Lehtonen HJ; Lehtonen R; Pukkala E; Arola J; Launonen V; Aaltonen LA
    Int J Cancer; 2006 Jul; 119(2):283-7. PubMed ID: 16477632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases.
    Pan X; Zhang M; Yao J; Zeng H; Nie L; Gong J; Chen X; Xu M; Zhou Q; Chen N
    J Clin Pathol; 2019 Nov; 72(11):748-754. PubMed ID: 31262952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma.
    Liang J; Sun G; Pan X; Zhang M; Shen P; Zhu S; Zhao J; Zheng L; Zhao J; Chen Y; Yin X; Chen J; Hu X; Zeng Y; Chen J; Wang Y; Liu Z; Yao J; Su M; Huang R; Liao B; Wei Q; Li X; Zhou Q; Liu J; Shen Y; Liu Z; Chen N; Zeng H; Zhang X
    Genome Med; 2023 May; 15(1):31. PubMed ID: 37131267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-DOPA decarboxylase mRNA levels provide high diagnostic accuracy and discrimination between clear cell and non-clear cell subtypes in renal cell carcinoma.
    Papadopoulos EI; Petraki C; Gregorakis A; Chra E; Fragoulis EG; Scorilas A
    Clin Biochem; 2015 Jun; 48(9):590-5. PubMed ID: 25721989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinoma.
    Sato A; Nagase H; Obinata D; Fujiwara K; Fukuda N; Soma M; Yamaguchi K; Kawata N; Takahashi S
    Int J Oncol; 2013 Nov; 43(5):1441-6. PubMed ID: 23969530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma.
    Gardie B; Remenieras A; Kattygnarath D; Bombled J; Lefèvre S; Perrier-Trudova V; Rustin P; Barrois M; Slama A; Avril MF; Bessis D; Caron O; Caux F; Collignon P; Coupier I; Cremin C; Dollfus H; Dugast C; Escudier B; Faivre L; Field M; Gilbert-Dussardier B; Janin N; Leport Y; Leroux D; Lipsker D; Malthieu F; McGilliwray B; Maugard C; Méjean A; Mortemousque I; Plessis G; Poppe B; Pruvost-Balland C; Rooker S; Roume J; Soufir N; Steinraths M; Tan MH; Théodore C; Thomas L; Vabres P; Van Glabeke E; Meric JB; Verkarre V; Lenoir G; Joulin V; Deveaux S; Cusin V; Feunteun J; Teh BT; Bressac-de Paillerets B; Richard S;
    J Med Genet; 2011 Apr; 48(4):226-34. PubMed ID: 21398687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2.
    Perrier-Trudova V; Huimin BW; Kongpetch S; Huang D; Ong P; Le Formal A; Poon SL; Siew EY; Myint SS; Gad S; Gardie B; Couvé S; Foong YM; Choudhury Y; Poh J; Ong CK; Toh CK; Ooi A; Richard S; Tan MH; Teh BT
    Anticancer Res; 2015 Dec; 35(12):6639-53. PubMed ID: 26637880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flotillin-1 expression in human clear-cell renal cell carcinoma is associated with cancer progression and poor patient survival.
    Zhang Y; Li J; Song Y; Chen F; Pei Y; Yao F
    Mol Med Rep; 2014 Aug; 10(2):860-6. PubMed ID: 24913320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. WWOX protein expression varies among RCC histotypes and downregulation of WWOX protein correlates with less-favorable prognosis in clear RCC.
    Lin JT; Tzai TS; Liao CY; Wang JS; Wu TT; Wang HY; Wu CH; Yu CC; Lu PJ
    Ann Surg Oncol; 2013 Jan; 20(1):193-9. PubMed ID: 22555346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peroxisome proliferator-activated receptor gamma is frequently underexpressed in renal cell carcinoma.
    Yuan J; Takahashi A; Masumori N; Itoh N; Tsukamoto T
    Int J Urol; 2006 Mar; 13(3):265-70. PubMed ID: 16643621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma.
    Goelden U; Pfoertner S; Hansen W; Toepfer T; von Knobloch R; Hofmann R; Buer J; Schrader AJ
    Urol Int; 2005; 75(3):269-76. PubMed ID: 16215318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer.
    Yang Y; Valera V; Sourbier C; Vocke CD; Wei M; Pike L; Huang Y; Merino MA; Bratslavsky G; Wu M; Ricketts CJ; Linehan WM
    Cancer Genet; 2012; 205(7-8):377-90. PubMed ID: 22867999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue.
    Jabs WJ; Busse M; Krüger S; Jocham D; Steinhoff J; Doehn C
    Kidney Int; 2005 Nov; 68(5):2103-10. PubMed ID: 16221209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.